Literature DB >> 11156389

Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression.

K Yoshidome1, M A Shibata, C Couldrey, K S Korach, J E Green.   

Abstract

Although several lines of epidemiological evidence suggest that estrogen exposure influences the incidence of breast cancer development, the mechanisms by which estrogen may stimulate the formation of breast cancer remain poorly understood. We have explored how alterations in estrogen exposure can influence the development of mammary cancer in the C3(1)/T(AG) transgenic model, where estrogen levels and estrogen receptor alpha (ERalpha) expression do not appear to modify the level of transgene expression. The C3(1)/T(AG) transgene becomes transcriptionally active in mammary ductal target cells at 3 weeks of age after the estrogen-induced differentiation of the mammary epithelial anlage to the ductal outgrowth stage. Complete maturation of the mammary ductal tree, however, is not required for cancer development because tumors arise in animals where ductal branching and terminal end bud formation have been prematurely arrested by ovariectomy. Mammary tumorigenesis in this model is promoted by increased estrogen exposure with the development of significantly more mammary intraepithelial neoplastic lesions and carcinomas associated with accelerated malignant conversion. The promotion of mammary tumors in this model appears to occur through an estrogen-induced proliferation and increase in the number of available target cells for transformation at the terminal ductal lobular units, as has been postulated to occur in women who receive hormone replacement therapy and/or by additional molecular mechanisms. We show, for the first time in a transgenic mouse model, that mammary tumor progression is associated with the loss of ERalpha expression, as has been often observed in human breast cancers with important clinical significance. Estrogen signaling may, therefore, serve different functions, depending upon the stage of tumorigenesis. ERbeta expression is up-regulated during tumor progression, although the functional significance of this remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156389

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer.

Authors:  Sneha Sundaram; Alex J Freemerman; Amy R Johnson; J Justin Milner; Kirk K McNaughton; Joseph A Galanko; Katharine M Bendt; David B Darr; Charles M Perou; Melissa A Troester; Liza Makowski
Journal:  Breast Cancer Res Treat       Date:  2013-11-12       Impact factor: 4.872

Review 2.  Genetically engineered ERα-positive breast cancer mouse models.

Authors:  Sarah A Dabydeen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

3.  Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.

Authors:  Lisa M Arendt; Teresa A Rose-Hellekant; Eric P Sandgren; Linda A Schuler
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.

Authors:  Daniel Medina; Frances Kittrell; Jamal Hill; Yun Zhang; Susan G Hilsenbeck; Reid Bissonette; Powel H Brown
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

5.  Dose-dependent benefits of quercetin on tumorigenesis in the C3(1)/SV40Tag transgenic mouse model of breast cancer.

Authors:  Jl Steiner; Jm Davis; Jl McClellan; Rt Enos; Ja Carson; R Fayad; M Nagarkatti; Ps Nagarkatti; D Altomare; Ke Creek; Ea Murphy
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

6.  A model of gene-environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation.

Authors:  J Bradley Williams; Diana Pang; Bertha Delgado; Masha Kocherginsky; Maria Tretiakova; Thomas Krausz; Deng Pan; Jane He; Martha K McClintock; Suzanne D Conzen
Journal:  Cancer Prev Res (Phila)       Date:  2009-09-29

Review 7.  The relevance of mouse models to understanding the development and progression of human breast cancer.

Authors:  D Craig Allred; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-08-14       Impact factor: 2.673

8.  Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status.

Authors:  Jisen Dai; Jinlong Jian; Maarten Bosland; Krystyna Frenkel; Güenther Bernhardt; Xi Huang
Journal:  Breast       Date:  2007-10-24       Impact factor: 4.380

9.  Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.

Authors:  Teresa A Rose-Hellekant; Andrew J Skildum; Olga Zhdankin; Amy L Greene; Ronald R Regal; Katherine D Kundel; Donald W Kundel
Journal:  Cancer Prev Res (Phila)       Date:  2009-04-28

10.  Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study.

Authors:  Sanaz A Jansen; Suzanne D Conzen; Xiaobing Fan; Erica J Markiewicz; Gillian M Newstead; Gregory S Karczmar
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.